Full video transcriptClick to expand
Auto-generated transcript of @becca_berkley's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Hey guys, I just wanted to jump on here and give you guys a little update
- 0:06So I have been doing the MOTS-c
- 0:10peptide for three weeks now
- 0:13And I just wanted to give a little bit of an update and let you guys kind of know what like I've noticed so far
- 0:20Entertainment purpose is only this is not medical advice. I'm just sharing with you what I've experienced so far
- 0:27So the MOTS-c is a mitochondrial
- 0:31peptide and it's basically going to
- 0:35Boost your metabolism. It's gonna help your fat burning. It's gonna help your endurance
- 0:41Like basically like it's just gonna help your workouts is gonna give you like a lot more endurance and stuff for your workouts
- 0:47And it's just gonna help with insulin sensitivity. Those are just a few things
- 0:52But anyways, so I'm on my third week
- 0:54I would tell you the biggest thing I've noticed is I normally have a pretty big
- 1:02Crash like around like two or three p.m. Every day and I and I do not fill any crash
- 1:08I normally like I'm like needing my energy tees and
- 1:14I haven't really necessarily needed those while I've been doing the MOTS-c. I
- 1:20Didn't feel as much at first, but this week I'm definitely feeling a difference
- 1:25I felt a little bit of a difference last week too, but like my first couple doses
- 1:30I didn't really feel too much of a difference, but yeah, I definitely
- 1:34Fill a difference in my energy just like I'm not having any crashes. So that's that's a big one for me because I always get
- 1:43So tired around two or three. So I'm pretty excited about that
- 1:46I have it noticed a huge difference in my workouts yet
- 1:51So we'll stay tuned for that
- 1:54But yeah, anyways, I'm really liking it so far. So I'm going to continue
MOTS-c peptide claims on TikTok: what the science says
Quick answer
MOTS-c is a mitochondrially encoded peptide with preclinical evidence for AMPK activation, insulin sensitization, and exercise capacity improvement, primarily from rodent studies. The creator reported reduced afternoon fatigue after roughly two weeks of use, which is plausible given proposed mechanisms but has not been validated in human clinical trials. No FDA-approved indication exists for MOTS-c, and human safety and dosing data remain unpublished in peer-reviewed literature.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For MOTS-c peptide claims on TikTok: what the science says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance
Foundational preclinical study (Cell Metabolism) where MOTS-c prevented diet-induced obesity and insulin resistance in mice; no human data.
PubMed
MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism
Review summarizing MOTS-c metabolic effects drawn from rodent and cell studies, not human trials.
PubMed
NAD+ metabolism and its roles in cellular processes during ageing
Core review for NAD+ decline, mitochondrial function, DNA repair, and aging biology.
PubMed
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Human NMN source for metabolic claims while keeping population limits clear.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
MOTS-c peptide claims on TikTok: what the science says is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "MOTS-c peptide claims on TikTok: what the science says" from Rebecca Berkley. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: MOTS-c is a mitochondrially encoded peptide with preclinical evidence for AMPK activation, insulin sensitization, and exercise capacity improvement, primarily from rodent studies.
The reason this review is not generic is the source wording and the canonical claim label "peptides here s a little update on my 3rd week of trying the mots c p." In this clip, the useful excerpt is: "Hey guys, I just wanted to jump on here and give you guys a little update So I have been doing the MOTS-c peptide for three weeks now And I just wanted to give a little bit of an update and let you guys kind of know what like I've noticed..." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (2015), MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism (2016), and Correlation between mitochondrial-derived peptide (MDP) levels and metabolic states: a systematic review and meta-analysis (2024), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
MOTS-c is a mitochondrially encoded peptide with preclinical evidence for AMPK activation, insulin sensitization, and exercise capacity improvement, primarily from rodent studies.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- MOTS-c is a mitochondrially encoded peptide with preclinical evidence for AMPK activation, insulin sensitization, and exercise capacity improvement, primarily from rodent studies. The creator reported reduced afternoon fatigue after roughly two weeks of use, which is plausible given proposed mechanisms but has not been validated in human clinical trials. No FDA-approved indication exists for MOTS-c, and human safety and dosing data remain unpublished in peer-reviewed literature.
- MOTS-c was first characterized in 2015 by Lee et al. (Cell Metabolism) as a mitochondrially encoded peptide, which is a real and scientifically unusual property, not just branding.
- The most cited human-relevant research on MOTS-c involves insulin sensitivity and metabolic stress, but no phase II or III clinical trials in humans have been published as of 2024.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- MOTS-c was first characterized in 2015 by Lee et al. (Cell Metabolism) as a mitochondrially encoded peptide, which is a real and scientifically unusual property, not just branding.
- The most cited human-relevant research on MOTS-c involves insulin sensitivity and metabolic stress, but no phase II or III clinical trials in humans have been published as of 2024.
- A 2019 Nature Communications study (Reynolds et al.) showed MOTS-c improved exercise capacity in older mice, but mouse-to-human translation for performance peptides has a poor track record.
- MOTS-c is not FDA-approved for any use. Compounded versions sold through wellness channels have not been evaluated for purity or consistent potency.
- Afternoon energy crashes disappearing over two to three weeks is also consistent with placebo response, which in well-designed trials can account for 20 to 40 percent of reported subjective improvements.
- Singh et al. (2023, Aging) published promising data on MOTS-c in aging models, but promising preclinical data has not translated to approved therapy for dozens of peptides that came before it.
- Anyone considering peptide therapy should consult a licensed clinician. A three-week TikTok update, even an honest one, cannot substitute for a personalized medical evaluation.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @becca_berkley actually say?
She reported three weeks of MOTS-c use and said the biggest change is that her usual afternoon energy crash, normally hitting around 2 or 3 p.m., has disappeared. She framed MOTS-c as a "mitochondrial peptide" that will "boost your metabolism," help with "fat burning," improve endurance during workouts, and support insulin sensitivity. She was honest that she hasn't noticed a workout difference yet and that the first few doses didn't do much. She also included an entertainment-only disclaimer upfront.
Credit where it's due: she didn't oversell a dramatic transformation, she acknowledged a delayed onset, and she stuck to personal experience rather than making hard health guarantees. That's a more measured approach than most peptide content on TikTok. But some of her mechanistic claims about what MOTS-c "is gonna" do deserve a closer look.
Does the science back this up?
The mitochondrial peptide framing is real, but the human evidence is thin. Most of what we know comes from animal studies, not clinical trials. MOTS-c is a mitochondrially encoded peptide, first described by Lee et al. (2015, Cell Metabolism), that does appear to influence metabolic regulation, particularly through AMPK activation. That part is legitimate science. The insulin sensitivity angle has some support too, at least in mice.
The fat burning and endurance claims are where things get ahead of the data. A 2019 study by Reynolds et al. in Nature Communications showed MOTS-c improved exercise capacity in older mice, but translating rodent endurance data to human gym performance is a significant leap. There are no published randomized controlled trials in humans showing MOTS-c improves body composition or workout endurance. The energy and crash reduction she describes is plausible if AMPK-related metabolic effects carry over to humans, but that remains speculative. Describing these as things MOTS-c "is gonna" do presents hypothesis as established outcome.
What did they get wrong (or right)?
The "mitochondrial peptide" label is accurate. MOTS-c is encoded in the mitochondrial genome, which makes it genuinely unusual among peptides and is not just marketing language. She gets credit for that specificity.
Where she overshoots: stating that MOTS-c "is gonna boost your metabolism" and "help your fat burning" as if these are confirmed human outcomes. They are effects observed in preclinical models. Presenting them as reliable personal benefits skips over the fact that human pharmacokinetics, dosing, and efficacy for MOTS-c are not established in peer-reviewed clinical literature.
Her subjective energy report, fewer afternoon crashes after about two weeks of use, is genuinely interesting and consistent with what AMPK activation could theoretically do. But it's also consistent with placebo effect, dietary changes, sleep variation, or any number of confounders she didn't mention. She can't know which it is, and neither can we.
- Accurate: MOTS-c is a mitochondrially derived peptide with metabolic effects in animal models
- Accurate: insulin sensitivity effects have preclinical support (Lee et al., 2015)
- Overstated: fat burning and endurance as near-certain human outcomes
- Unverifiable: her personal energy improvement as caused by MOTS-c specifically
What should you actually know?
MOTS-c is not FDA-approved for any indication. It is not a supplement. It exists in a regulatory gray zone, and the compounded peptide products circulating in wellness communities have not been evaluated for purity, potency, or safety in large-scale human trials. That matters before anyone considers using it.
The science here is early and genuinely interesting. Researchers like Bhupinder Singh and colleagues have published on MOTS-c's role in aging and metabolic stress (2023, Aging). But interesting early science and proven human therapy are two different things. Anyone watching this video should know that a three-week personal anecdote, even an honest one, cannot tell you whether this peptide works, what dose is safe, or what long-term effects look like.
If you're curious about peptides for metabolic support or recovery, that conversation belongs with a licensed clinician who can review your full health picture, not a TikTok comment section.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Rebecca Berkley · TikTok creator
6.7K views on this video
Here’s a little update on my 3rd week of trying the mots-c peptide! #wellness #peptide #pep #gym #gymgirls
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about mots-c was first characterized in 2015 by lee et al.?
MOTS-c was first characterized in 2015 by Lee et al. (Cell Metabolism) as a mitochondrially encoded peptide, which is a real and scientifically unusual property, not just branding.
What does the video say about the most cited human-relevant research on mots-c involves insulin sensitivity?
The most cited human-relevant research on MOTS-c involves insulin sensitivity and metabolic stress, but no phase II or III clinical trials in humans have been published as of 2024.
What does the video say about a 2019 nature communications study (reynolds et al.) showed mots-c?
A 2019 Nature Communications study (Reynolds et al.) showed MOTS-c improved exercise capacity in older mice, but mouse-to-human translation for performance peptides has a poor track record.
What does the video say about mots-c?
MOTS-c is not FDA-approved for any use. Compounded versions sold through wellness channels have not been evaluated for purity or consistent potency.
What does the video say about afternoon energy crashes disappearing over two to three weeks?
Afternoon energy crashes disappearing over two to three weeks is also consistent with placebo response, which in well-designed trials can account for 20 to 40 percent of reported subjective improvements.
What does the video say about singh et al. (2023, aging) published promising data on mots-c?
Singh et al. (2023, Aging) published promising data on MOTS-c in aging models, but promising preclinical data has not translated to approved therapy for dozens of peptides that came before it.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Rebecca Berkley, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.